Results 21 to 30 of about 7,162 (211)
Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation [PDF]
, 2023 Introduction: Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence.
the Dutch aHUS Working Group
core
Saudi Journal of Kidney Diseases and Transplantation, 2018 Atypical hemolytic uremic syndrome (aHUS) is characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and widespread damage to multiple organs including the kidney.
Mohammad A Hossain +8 more
doaj +1 more source
Journal of Comparative Effectiveness Research, 2023 Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden.
Teri J Mauch +12 more
doaj +1 more source
Korean Journal of Transplantation, 2021 Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by complement dysregulation that may involve the extra-renal system. Without appropriate prophylactic treatment, aHUS commonly recur after kidney transplantation (KT).
Min Hye Kim +5 more
doaj +1 more source
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS. [PDF]
Nephrol Dial TransplantBACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is a rare but severe condition caused by complement dysregulation. Eculizumab prophylaxis prevents recurrence and improves survival, yet the benefits of lifelong treatment for patients are uncertain
Orozco-Leal G +14 more
europepmc +2 more sources
Pediatric Atypical Hemolytic Uremic Syndrome Advances
Cells, 2021 Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by dysregulation of the alternate pathway. The diagnosis of aHUS is one of exclusion, which complicates its early detection and corresponding intervention to mitigate its high ...
Rupesh Raina +9 more
doaj +1 more source
Atypical hemolytic uremic syndrome
Renal Replacement Therapy, 2017 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure.
Yoko Yoshida +2 more
doaj +1 more source
Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults
Frontiers in Medicine, 2023 BackgroundDespite significant advances in therapeutic management of atypical hemolytic uremic syndrome (aHUS), guidelines are not timely updated and achieving a consensus on management recommendations remains a topic of ongoing discussion.MethodsA ...
Ana Ávila +4 more
doaj +1 more source
Remission of aHUS neurological damage with eculizumab [PDF]
Clinical Kidney Journal, 2015 Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic ...
Ávila, Ana +5 more
openaire +2 more sources
Genetic variants of Brazilian aHUS cohort patients in renal transplantation.
, 2021 Genetic variants of Brazilian aHUS cohort patients in renal transplantation.
Hong Si Nga (4592092) +9 more
core +1 more source